Harnessing Exosome Biology for MultiCancer Early Detection

About us

Rivela envisions a world in which a simple blood test will be sufficient for the early detection of multiple cancers, enabling routine identification of tumours in asymptomatic patients and, ultimately, improving disease outcomes and people’s quality of life.

Learn more

Rivela's liquid biopsy technology enables the earliest possible identification of tumours

Learn more
Challenging Current Liquid Biopsy Paradigms

Rivela is aiming to make all this available globally through standard laboratory techniques, avoiding the need for complex Next-Gen Sequencing, at a price point that revolutionises access to life-saving cancer interventions, whoever you are or where you live. By achieving this goal, we will reduce the devastating impact of the rise of global cancer rates and improve the lives of those affected by the disease.

Information on cookies on this site

This site uses anonymous technical and statistical cookies, necessary for its operation.

Read more x